### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Proposed Single Technology Appraisal (STA)**

# Grazoprevir-elbasvir for treating chronic hepatitis C [ID842]

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company	General
Merck Sharp & Dohme (grazoprevir–	Allied Health Professionals Federation
elbasvir)	<ul> <li>Board of Community Health Councils in Wales</li> </ul>
Patient/carer groups	<ul> <li>British National Formulary</li> </ul>
Addaction	Care Quality Commission
<ul> <li>Addiction Today (Addiction Recovery</li> </ul>	<ul> <li>Department of Health, Social Services</li> </ul>
Foundation)	and Public Safety for Northern Ireland
<ul> <li>African Health Policy Network</li> </ul>	Drugs Action
Black Health Agency	<ul> <li>Healthcare Improvement Scotland</li> </ul>
British Liver Trust	<ul> <li>Medicines and Healthcare Products</li> </ul>
Compass UK	Regulatory Agency
GMFA - The Gay Men's Health	<ul> <li>National Association of Primary Care</li> </ul>
Charity	<ul> <li>National Pharmacy Association</li> </ul>
HIV i Base	NHS Alliance
Liver4Life	<ul> <li>NHS Blood and Transplant</li> </ul>
Muslim Council of Britain	<ul> <li>NHS Commercial Medicines Unit</li> </ul>
NAM Publications	<ul> <li>NHS Confederation</li> </ul>
National AIDS Trust	<ul> <li>Scottish Medicines Consortium</li> </ul>
Positively UK	
South Asian Health Foundation	Possible comparator companies
Specialised Healthcare Alliance	AbbVie (ombitasvir/paritaprevir/ritonavir,
Terrence Higgins Trust	dasabuvir)
The Hepatitis C Trust	Bristol-Myers Squibb Pharmaceuticals
UK Harm Reduction Alliance	(daclatasvir)
YouthNet	<ul> <li>Gilead Sciences (ledipasvir–sofosbuvir, sofosbuvir)</li> </ul>
Professional groups	Janssen (simeprevir, telaprevir)
Association for Clinical Biochemistry	Meda Pharmaceuticals (ribavirin)
and Laboratory Medicine	Merck Sharp & Dohme (boceprevir,
British Association for Sexual Health	peginterferon alfa 2b, ribavirin)
and HIV	Mylan UK (ribavirin)
<ul> <li>British Association for the Study of the Liver</li> </ul>	<ul> <li>Roche Products (peginterferon alfa 2a, ribavirin)</li> </ul>
<ul> <li>British Association for the Study of the Liver Nurses Forum</li> </ul>	Teva UK (ribavirin)
British Geriatrics Society	Relevant research groups

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal of grazoprevir–elbasvir for treating chronic hepatitis C [ID842] Issue date: August 2015 Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul> <li>British HIV Association</li> <li>British Infection Association</li> <li>British Liver Nurses Forum</li> <li>British Society of Gastroenterology</li> <li>British Transplantation Society</li> <li>British Viral Hepatitis Group</li> <li>HCV Action</li> <li>Hepatitis Nurse Specialist Forum</li> <li>Infection Control Nurses Association</li> <li>Medical Foundation for AIDS &amp; Sexual Health</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society for General Microbiology</li> <li>UK Clinical Pharmacy Association</li> <li>UK Clinical Virology Network</li> </ul>	<ul> <li>Cochrane Hepato-Biliary Group</li> <li>Foundation for Liver Research</li> <li>MRC Clinical Trials Unit</li> <li>National Institute of Health Research</li> <li>UCL Centre for Sexual Health &amp; HIV Research</li> <li>Evidence Review Group</li> <li>Evidence Review Group tbc</li> <li>National Institute for Health Research Health Technology Assessment Programme</li> <li>Associated Guideline Groups</li> <li>National Clinical Guidelines Centre</li> <li>Associated Public Health Groups</li> <li>Public Health England</li> <li>Public Health Wales</li> </ul>
<ul><li>Department of Health</li><li>NHS England</li><li>NHS Bradford City CCG</li></ul>	
<ul><li>NHS Eastern Cheshire CCG</li><li>Welsh Government</li></ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: of the companies that markets comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

National Institute for Health and Care Excellence

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.